NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value
Symbol
NBIX on Nasdaq
Shares outstanding
99,963,154
Price per share
$140.62
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
99,269,799
Total reported value
$14,038,339,206
% of total 13F portfolios
0.01%
Share change
+2,436,756
Value change
+$326,831,924
Number of holders
713
Price from insider filings
$140.62
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 12% $1,274,648,181 12,052,271 BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 10% $1,071,315,697 10,129,687 The Vanguard Group 28 Feb 2025
DODGE & COX 5.6% $585,341,834 5,534,624 Dodge & Cox 31 Mar 2025
JPMORGAN CHASE & CO 5.2% $737,244,254 5,198,084 JPMORGAN CHASE & CO. 31 Dec 2025
STATE STREET CORP 4.8% $517,286,649 4,891,137 STATE STREET CORPORATION 31 Dec 2024

As of 31 Dec 2025, 713 institutional investors reported holding 99,269,799 shares of NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX). This represents 99% of the company’s total 99,963,154 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX) together control 65% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 13% 12,830,597 +0.98% 0.03% $1,819,763,595
VANGUARD GROUP INC 9.7% 9,700,301 -0.06% 0.02% $1,375,793,692
Dodge & Cox 5.5% 5,508,042 -0.87% 0.42% $781,205,597
JPMORGAN CHASE & CO 5.2% 5,200,356 +9.9% 0.05% $737,566,619
STATE STREET CORP 4.2% 4,242,681 -2.4% 0.02% $601,739,446
AQR CAPITAL MANAGEMENT LLC 3.3% 3,271,706 +18% 0.24% $462,651,883
RENAISSANCE TECHNOLOGIES LLC 2.2% 2,238,797 -7.4% 0.49% $317,528,579
GEODE CAPITAL MANAGEMENT, LLC 2.1% 2,059,282 +1.7% 0.02% $291,341,652
PRICE T ROWE ASSOCIATES INC /MD/ 1.9% 1,872,240 -35% 0.03% $265,541,000
WELLINGTON MANAGEMENT GROUP LLP 1.7% 1,744,560 -3.7% 0.04% $247,430,944
Bellevue Group AG 1.7% 1,703,304 -3.4% 4.6% $241,579,606
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.4% 1,395,902 +47% 0.23% $197,989,000
LOS ANGELES CAPITAL MANAGEMENT LLC 1.3% 1,291,278 +7.4% 0.62% $178,248,014
NORTHERN TRUST CORP 1.2% 1,221,184 +32% 0.02% $173,200,527
MORGAN STANLEY 1.2% 1,209,377 -34% 0.01% $171,526,238
DEERFIELD MANAGEMENT COMPANY, L.P. 1.2% 1,184,345 0% 2.2% $167,975,651
NORGES BANK 1.1% 1,146,896 0.02% $162,664,260
RTW INVESTMENTS, LP 1.1% 1,062,072 0% 1.5% $150,633,672
TWO SIGMA INVESTMENTS, LP 0.99% 984,811 +183% 0.21% $139,675,744
UBS Group AG 0.98% 983,528 +170% 0.03% $139,493,777
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.85% 850,632 +2.5% 0.02% $120,645,137
TWO SIGMA ADVISERS, LP 0.84% 842,592 +466% 0.23% $119,504,823
ARMISTICE CAPITAL, LLC 0.82% 820,240 +18% 2.8% $116,334,639
Pictet Asset Management Holding SA 0.78% 776,934 +12% 0.11% $110,304,874
BRAIDWELL LP 0.75% 751,534 -15% 3.4% $106,590,067

Institutional Holders of NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 99,269,799 $14,038,339,206 +$326,831,924 $141.83 713
2025 Q3 96,993,000 $13,610,996,356 -$262,852,482 $140.38 642
2025 Q2 98,821,219 $12,420,453,326 +$494,184,481 $125.69 578
2025 Q1 95,485,987 $10,559,467,994 +$7,244,935 $110.60 579
2024 Q4 94,376,685 $12,879,887,685 +$230,192,847 $136.50 596
2024 Q3 93,003,458 $10,720,376,398 -$150,384,737 $115.22 570
2024 Q2 93,636,708 $12,887,512,754 +$47,493,212 $137.67 589
2024 Q1 93,218,731 $12,853,312,563 +$116,424,918 $137.92 580
2023 Q4 92,326,586 $12,160,216,767 +$5,244,067 $131.76 545
2023 Q3 92,001,152 $10,350,228,156 +$38,916,412 $112.50 508
2023 Q2 91,514,317 $8,634,655,568 +$37,920,952 $94.30 452
2023 Q1 90,892,702 $9,194,138,307 +$67,286,199 $101.22 481
2022 Q4 90,124,434 $10,754,797,482 +$104,201,709 $119.44 525
2022 Q3 90,489,863 $9,610,613,890 -$33,115,379 $106.21 451
2022 Q2 89,687,591 $8,740,480,340 -$27,492,643 $97.48 426
2022 Q1 90,130,456 $8,447,849,857 +$146,450,381 $93.75 413
2021 Q4 89,152,258 $7,586,914,975 -$142,540,543 $85.17 389
2021 Q3 90,241,905 $8,655,761,280 -$94,927,615 $95.91 390
2021 Q2 91,390,637 $8,892,923,286 -$379,127,377 $97.32 398
2021 Q1 95,118,085 $9,245,217,222 +$547,907,714 $97.25 410
2020 Q4 89,436,431 $8,572,935,331 -$29,252,870 $95.85 394
2020 Q3 89,711,420 $8,625,616,767 -$165,135,029 $96.16 410
2020 Q2 91,024,593 $11,119,662,216 +$58,260,926 $122.00 409
2020 Q1 90,478,199 $7,833,712,957 +$134,190,014 $86.55 359
2019 Q4 88,959,948 $9,559,971,817 -$103,711,811 $107.49 384
2019 Q3 89,723,577 $8,083,967,833 +$131,837,632 $90.11 326
2019 Q2 88,956,333 $7,509,818,200 +$405,236,838 $84.43 295
2019 Q1 88,419,309 $7,789,441,265 -$73,607,084 $88.10 322
2018 Q4 89,596,633 $6,383,418,413 -$95,226,490 $71.41 320
2018 Q3 88,628,011 $10,894,534,004 -$350,597,450 $122.95 340
2018 Q2 91,900,554 $9,027,143,703 +$3,561,671 $98.24 273
2018 Q1 92,039,747 $7,632,734,396 -$146,781,309 $82.93 262
2017 Q4 93,842,806 $7,281,125,612 -$128,562,595 $77.59 260
2017 Q3 95,978,123 $5,879,367,235 +$103,870,885 $61.28 221
2017 Q2 94,854,554 $4,360,458,912 +$660,704,567 $46.00 220
2017 Q1 85,050,694 $3,682,149,679 +$238,897,265 $43.30 214
2016 Q4 84,375,738 $3,265,417,619 -$80,513,423 $38.70 223
2016 Q3 85,702,329 $4,337,642,435 +$54,561,657 $50.64 238
2016 Q2 84,777,416 $3,856,100,900 -$118,084,536 $45.45 225
2016 Q1 87,607,298 $3,462,890,615 +$138,072,840 $39.55 210
2015 Q4 83,420,495 $4,719,017,664 +$51,306,797 $56.57 216
2015 Q3 82,822,881 $3,294,868,792 -$23,148,713 $39.79 203
2015 Q2 83,373,554 $3,981,499,654 -$77,877,733 $47.76 193
2015 Q1 85,169,982 $3,380,013,692 +$405,563,981 $39.71 171
2014 Q4 75,151,940 $1,678,841,423 +$53,086,515 $22.34 132
2014 Q3 73,295,238 $1,148,500,395 +$43,815,414 $15.67 132
2014 Q2 70,444,189 $1,045,232,097 +$8,065,092 $14.84 124
2014 Q1 69,779,790 $1,123,235,688 +$194,871,032 $16.10 120